Yungjin Pharm to mull pain-in capital increase of 20 billion won

Yungjin Pharm unveiled a plan to lure domestic investors via its pain-in capital increase of 20 billion won by designating the third party on March 2004.

To that end, the company will hold its special shareholders meeting on coming December 19, saying that G&F consortium including KT&G will undertake the investment plan as a precondition that Youngjin will become a non-listed company at the...